Managed Care

Biologics trend leads pharmaceuticals

The general stabilization in per-capita medical claims cost — what services cost the health plan before the member is charged — for the managed care industry has not, for the most part, spilled over to biologics, according to a survey by the Segal Co. The consulting company's ninth annual survey of health insurers, PBMs, and third-party administrators forecasts "continued declines in trends in 2006 for every coverage surveyed."

However, the company adds that, "the projected trend for biotechnology or specialty drugs is increasing at a rapid rate: 21.6 percent in 2006, approximately 8 percentage points above aggregate retail trend. The 2006 projection was obtained through a survey taken in summer 2005.

Burden of supplying pharmaceuticals, biologics

Note: No figures available for cost of biologics in 2004.

SOURCE: 2006 Segal Health Plan Cost Trend Survey.

Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

  • Doug Jones and the ACA, Epic misses a White House meeting, and man caves for man-flu sufferers
  • CVS-Aetna deal may trigger merger mania, Johns Hopkins criticized for lack of asthma prevention, & Columbia sees free-ride future for all of its med students

PTCommunity news

New drug approvals, clinical trials, drug management. Three times per week.